Elizabeth Mack to Systemic Inflammatory Response Syndrome
This is a "connection" page, showing publications Elizabeth Mack has written about Systemic Inflammatory Response Syndrome.
Connection Strength
1.093
-
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 14; 71(2):52-58.
Score: 0.206
-
Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021 07 01; 385(1):23-34.
Score: 0.198
-
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021 05 01; 78(5):536-547.
Score: 0.196
-
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 03 16; 325(11):1074-1087.
Score: 0.194
-
Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children. Pediatrics. 2021 05; 147(5).
Score: 0.193
-
Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C. Pediatrics. 2022 09 01; 150(3).
Score: 0.054
-
Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022 05 27; 13(1):2979.
Score: 0.053